Proxy Vote Update: FIRST WAVE BIOPHARMA, INC. (12/17/2021)

Below are the resources for and the results of our recent Proxy Vote on behalf of our clients:

Proxy Materials:

rF Voting Results:

Vote Board of Directors:
1. Election of Director: James Sapirstein – Against. President, CEO and Chairman are the same person.
2. Election of Director: Edward J. Borkowski – FOR
3. Election of Director: Charles J. Casamento – FOR
4. Election of Director: Alastair Riddell – FOR
5. Election of Director: Gregory Oakes – FOR
6. Election of Director: Terry Coelho – FOR

Approval to Amend our Charter to Increase the Total Number of Authorized Shares of our Common Stock by 25,000,000 Shares to 50,000,000 Shares. – Abstain
Ratification of Mazars USA LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2021. – FOR
Approval of the Adjournment of the Annual Meeting to the Extent There Are Insufficient Proxies at the Annual Meeting to Approve Any One or More of the Foregoing Proposals. – Abstain

Disclosures

This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial’s solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.

Join our newsletter

Newsletter Signup

Phil Ratcliff

Phil Ratcliff, President of rebel Financial, is a senior financial advisor that holds an AIF®, CFP®, ChFC®, and CLU® certifications. He started his career at American Express Financial Advisors in 2003, then moved to AXA Advisors for 7 years before founding rebel Financial LLC in 2013.